1-4 of 4
Claire Bonfils
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract LBA018: Discovery of novel functional TROP2 antibodies for treatment of epithelial cancers

Israel Matos, Hiba Zahreddine, Yahya Ashraf, Aditya Pandey, Emily Chen, Liying Gong, Alex Zhou, Claire Bonfils, Aniel Moya, Yun Cui, Xiaowei Wang, Elijus Undzyz, Shugang Yao, Jacynthe Toulouse, Dominic Hou, Gordon Ngan, Luis da Cruz, David Young
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): LBA018.
https://doi.org/10.1158/1535-7163.TARG-21-LBA018
Published: 01 December 2021
View article titled, Abstract LBA018: Discovery of novel functional TROP2 antibodies for treatment of epithelial cancers
Journal Articles

Abstract P200: Pre-clinical development of a dopamine receptor 2, PD-1 and CD47 trispecific antibody for treatment of small cell lung cancer

Shugang Yao, Yun Cui, Anna Kazanats, Liying Gong, Claire Bonfils, Dominic Hou, Emily Chen, Elijus Undzys, Jacynthe Toulouse, Milica Krstic, Hiba Zahreddine, Israel Matos, Alex Zhou, Aniel Moya-Torres, Richard Wargachuk, Carl Gay, Lauren Byers, Gordon Ngan, Luis da Cruz, David Young
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P200.
https://doi.org/10.1158/1535-7163.TARG-21-P200
Published: 01 December 2021
View article titled, Abstract P200: Pre-clinical development of a dopamine receptor 2, PD-1 and CD47 trispecific antibody for treatment of small cell lung cancer
Journal Articles

Abstract A95: The determination of the maximum tolerated dose (MTD) of MGCD265 on an intermittent schedule: Phase I study results (Study 265-102).

Jennifer Wheler, Razelle Kurzrock, Elizabeth I. Heath, Gerald S. Falchook, Christiane R. Maroun, Michel A. Drouin, Manuela Juretic, Claire Bonfils, Andre Karam, Jeffrey M. Besterman, James Wang, Patricia LoRusso
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A95.
https://doi.org/10.1158/1535-7163.TARG-11-A95
Published: 12 November 2011
View article titled, Abstract A95: The determination of the maximum tolerated dose (MTD) of MGCD265 on an intermittent schedule: Phase I study results (Study 265-102).
Journal Articles

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

Marielle Fournel, Claire Bonfils, Yu Hou, Pu Theresa Yan, Marie-Claude Trachy-Bourget, Ann Kalita, Jianhong Liu, Ai-Hua Lu, Nancy Z. Zhou, Marie-France Robert, Jeffrey Gillespie, James J. Wang, Hélène Ste-Croix, Jubrail Rahil, Sylvain Lefebvre, Oscar Moradei, Daniel Delorme, A. Robert MacLeod, Jeffrey M. Besterman, Zuomei Li
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (4): 759–768.
https://doi.org/10.1158/1535-7163.MCT-07-2026
Published: 15 April 2008
View article titled, MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <em>in vitro</em> and <em>in vivo</em>
Open the PDF for MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <em>in vitro</em> and <em>in vivo</em> in another window
Includes: Supplementary data